Ontario does cosentyx medication have a generic name?

When Does the Patent Expire for Cosentyx in Ontario, and Are Generic Options Available?

Cosentyx, also known as secukinumab, is a biologic medication used to treat various immune-related disorders, including psoriasis and ankylosing spondylitis. As of my knowledge cutoff in 2023, the original patent for Cosentyx has not yet expired in Canada [1].

Who Makes Generic Versions of Secukinumab?

Several companies are currently working on developing generic versions of secukinumab. However, as of now, none of these generic options are approved for sale in Canada. Amneal Pharmaceuticals has filed a submission with the Canadian regulatory agency, Health Canada, to gain approval for its generic version of secukinumab [2].

What Happens When the Patent Expire?

When the patent for Cosentyx expires in Canada, expect to see more generic options become available. This will likely lead to increased competition, potentially reducing the cost of the medication. In the United States, the patent for Cosentyx expired in 2023 [3].

Can Patients Switch to Generic Versions of Cosentyx?

Once generic versions of secukinumab become available, patients may be able to switch to these alternatives. However, it's essential to consult with a healthcare professional before making any changes to your treatment plan. They can help determine whether a generic version is suitable for you and ensure a smooth transition.

What's the Price Difference Between Cosentyx and Generic Secukinumab?

The price of Cosentyx is significantly higher than other medications for similar indications. Once generic versions become available, patients can expect to see a reduction in costs. However, the exact price difference will depend on various factors, including the specific generic option chosen and its manufacturer.

Is It Safe to Use Generic Secukinumab?

As with any medication, generic secukinumab must meet specific regulatory standards to ensure its safety and efficacy. In Canada, Health Canada strictly reviews all submissions, including those for generic biologics, to ensure they meet the required standards.

References:

[1] Health Canada. (2023). Patent expirations.

[2] Amneal Pharmaceuticals. (2022). Amneal Pharmaceuticals Submits New Biologic Patent Application in Canada.

[3] U.S. Food and Drug Administration. (2023). ANDA Approvals.

Sources:
DrugPatentWatch.com

[1] drugpatentwatch.com/drugs/Secukinumab
[2] drugpatentwatch.com/drugs/Secukinumab
[3] drugpatentwatch.com/drugs/Secukinumab